Replimune Group (NASDAQ:REPL) Announces Earnings Results, Beats Estimates By $0.07 EPS

Replimune Group (NASDAQ:REPL) issued its quarterly earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07, Zacks reports.

Replimune Group Stock Down 2.0 %

NASDAQ REPL traded down $0.24 on Wednesday, hitting $11.95. 129,942 shares of the stock traded hands, compared to its average volume of 1,036,219. The stock has a 50-day moving average of $11.42 and a 200 day moving average of $9.49. Replimune Group has a twelve month low of $4.92 and a twelve month high of $12.97. The company has a market capitalization of $816.42 million, a P/E ratio of -3.91 and a beta of 1.19. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on REPL shares. Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm started coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a report on Tuesday. Finally, JPMorgan Chase & Co. increased their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Replimune Group has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.